Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.82 |
| ▸ | GAK | O14976 | 3/20 | 0.82 |
| ▸ | FBP1 | P09467 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.78 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.78 |
| ▸ | BUB1 | O43683 | 2/20 | 0.78 |
| ▸ | STK10 | O94804 | 2/20 | 0.78 |
| ▸ | ABL1 | P00519 | 2/20 | 0.78 |
| ▸ | LCK | P06239 | 2/20 | 0.78 |
| ▸ | LYN | P07948 | 2/20 | 0.78 |
| ▸ | RET | P07949 | 2/20 | 0.78 |
| ▸ | SRC | P12931 | 2/20 | 0.78 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.78 |
| ▸ | FECH | P22830 | 2/20 | 0.78 |
| ▸ | KDR | P35968 | 2/20 | 0.78 |
| ▸ | FLT3 | P36888 | 2/20 | 0.78 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.78 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28522667 | 0.96 | EGFR (0.82) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL28523359 | 0.96 | EGFR (0.82) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL29577864 | 0.95 | EGFR (0.79) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL17038717 | 0.93 | EGFR (0.76) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL24535454 | 0.91 | EGFR (0.94) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL2129452 | 0.91 | EGFR (0.94) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL1507548 | 0.91 | EGFR (0.79) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL29578618 | 0.91 | EGFR (0.79) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL667895 | 0.91 | EGFR (1.00) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL1731532 | 0.90 | EGFR (0.87) | EGFRGAKFBP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106892898-B | Azasugar-derived quinazolines | 陕西师范大学 | 2021-02-05 | — | — | CN | disclosed |
| EP-2780342-B1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-06-01 | — | — | EP | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| EP-2780342-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| WO-2013071697-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013071697-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | ABL1, PRKDC, JAK2 | EGFR 460/4885GAK 180/4885FBP1 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.